|PERNIX THERAPEUTICS HOLDINGS, INC. TO REPORT THIRD QUARTER 2015 FINANCIAL RESULTS ON THURSDAY, NOVEMBER 5, 2015|
MORRISTOWN, NJ – October 22, 2015 – Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX), a specialty pharmaceutical company, announced today that it will release its 2015 third quarter financial results on Thursday, November 5, 2015, before the market opens.
Doug Drysdale, Chairman and Chief Executive Officer, and Sanjay Patel, Chief Financial Officer, will host a conference call to discuss the results as follows:
Date: Thursday, November 5, 2015
The presentation will be webcast and available on the Investors section of the Company’s website at http://www.pernixtx.com/investors/webcasts-presentations/. A replay of the webcast will be available for 30 days after the date of the presentation.
About Pernix Therapeutics
Pernix Therapeutics is a specialty pharmaceutical business with a focus on acquiring, developing and commercializing prescription drugs primarily for the U.S. market. The Company targets underserved therapeutic areas such as CNS, including neurology and pain management, and has an interest in expanding into additional specialty segments. The Company promotes its branded products to physicians through its two Pernix sales forces and markets its generic portfolio through its wholly owned subsidiaries, Macoven Pharmaceuticals, LLC and Cypress Pharmaceutical, Inc.
To learn more about Pernix Therapeutics, visit www.pernixtx.com.
Pernix Therapeutics Holdings, Inc.
Lisa Wilson, (212) 452-2793